Evidence map›Paper›PMID 38532486›Full record

ArticleFluids and barriers of the CNS2024

Cognitive decline, Aβ pathology, and blood-brain barrier function in aged 5xFAD mice.

Geetika Nehra, Sasivimon Promsan, Ruedeemars Yubolphan, Wijitra Chumboatong, Pornpun Vivithanaporn, Bryan J Maloney, Anusorn Lungkaphin, Bjoern Bauer, Anika M S Hartz

Open access · goldAbstract read
In one paragraph

Article in Fluids and barriers of the CNS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Geetika NehraSanders-Brown Center On Aging, University of Kentucky, 760 Press Ave, 124 HKRB, Lexington, KY, 40536-0679, USA.
Sasivimon PromsanSanders-Brown Center On Aging, University of Kentucky, 760 Press Ave, 124 HKRB, Lexington, KY, 40536-0679, USA.
Ruedeemars YubolphanDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Wijitra ChumboatongSanders-Brown Center On Aging, University of Kentucky, 760 Press Ave, 124 HKRB, Lexington, KY, 40536-0679, USA.
Pornpun VivithanapornFaculty of Medicine Ramathibodi Hospital, Chakri Naruebodindra Medical Institute, Mahidol University, Nakhon Pathom, Thailand.
Bryan J MaloneySanders-Brown Center On Aging, University of Kentucky, 760 Press Ave, 124 HKRB, Lexington, KY, 40536-0679, USA.
Anusorn LungkaphinDepartment of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Bjoern BauerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, USA.
Anika M S HartzSanders-Brown Center On Aging, University of Kentucky, 760 Press Ave, 124 HKRB, Lexington, KY, 40536-0679, USA. anika.hartz@uky.edu.
University of Kentucky · USRamathibodi Hospital · THChiang Mai University · TH

Funding

Blood-Brain Barrier Repair in Alzheimer’s Disease with EpilepsyR01AG075583 · NIA · UNIVERSITY OF KENTUCKY · PI Bjoern Bauer, Anika M.S. Hartz · 2022 to 2026
$3.6M
Bisphenol-Induced Blood-Brain Barrier Dysfunction in Alzheimer’s DiseaseR01NS133250 · NINDS · UNIVERSITY OF KENTUCKY · PI Anika M.S. Hartz · 2023 to 2026
$2.9M
Blood-brain barrier P-glycoprotein: a new target for Alzheimer's diseaseR01AG039621 · NIA · UNIVERSITY OF MINNESOTA · PI HARTZ, ANIKA M.S. · 2011 to 2015
$1.5M
NIA NIH HHS R01 AG039621NIA NIH HHS R01 AG075583NIH HHS 2R01AG039621NIH HHS R01AG069968NIH HHS R01AG075583NINDS NIH HHS R01 NS133250
6 · The paper itself

Abstract

backgroundPatients with Alzheimer's disease (AD) develop blood-brain barrier dysfunction to varying degrees. How aging impacts Aβ pathology, blood-brain barrier function, and cognitive decline in AD remains largely unknown. In this study, we used 5xFAD mice to investigate changes in Aβ levels, barrier function, and cognitive decline over time.

methods5xFAD and wild-type (WT) mice were aged between 9.5 and 15.5 months and tested for spatial learning and reference memory with the Morris Water Maze (MWM). After behavior testing, mice were implanted with acute cranial windows and intravenously injected with fluorescent-labeled dextrans to assess their in vivo distribution in the brain by two-photon microscopy. Images were processed and segmented to obtain intravascular intensity, extravascular intensity, and vessel diameters as a measure of barrier integrity. Mice were sacrificed after in vivo imaging to isolate brain and plasma for measuring Aβ levels. The effect of age and genotype were evaluated for each assay using generalized or cumulative-linked logistic mixed-level modeling and model selection by Akaike Information Criterion (AICc). Pairwise comparisons were used to identify outcome differences between the two groups.

results5xFAD mice displayed spatial memory deficits compared to age-matched WT mice in the MWM assay, which worsened with age. Memory impairment was evident in 5xFAD mice by 2-threefold higher escape latencies, twofold greater cumulative distances until they reach the platform, and twice as frequent use of repetitive search strategies in the pool when compared with age-matched WT mice. Presence of the rd1 allele worsened MWM performance in 5xFAD mice at all ages but did not alter the rate of learning or probe trial outcomes. 9.5-month-old 15.5-month-old 5xFAD mice had twofold higher brain Aβ

conclusion5xFAD mice continue to develop spatial memory deficits and increased Aβ brain levels while aging. Given in vivo MP imaging limitations, further investigation with smaller molecular weight markers combined with advanced imaging techniques would be needed to reliably assess subtle differences in barrier integrity in aged mice.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesAnimalsBlood-Brain BarrierDisease Models, AnimalHumansInfantMemory DisordersMiceMice, TransgenicAmyloid beta-Peptides5xFADAβBlood–Brain BarrierPde6b rd1

Identifiers

PMID38532486
PMCPMC10967049
OpenAlexW4394760762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.